After pulling IPO plans, Artiva partners with Affimed to speed up NK cell therapy combo

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

The reasoning for withdrawing its IPO desires? Artiva Biotherapeutics had a different big plan to share — one that couldn’t be done under the constraints of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After pulling IPO plans, Artiva partners with Affimed to speed up NK cell therapy combo

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Af­ter pulling IPO plans, Arti­va part­ners with Af­fimed to speed up NK cell ther­a­py com­bo

Senior Reporter

Senior Editor

Sign up to read this article for free.

After pulling IPO plans, Artiva partners with Affimed to speed up NK cell therapy combo